Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.940704
Keywords
erlotinib; 1,2,3-triazole; IDO1; Attentive FP; antitumor
Categories
Funding
- Scientific and Technological Project of Henan Province
- National Natural Science Foundation of China
- [192102310142]
- [NSFC 21672106]
Ask authors/readers for more resources
Erlotinib is a targeted therapy drug for non-small-cell lung cancer, but its efficacy is limited due to drug resistance. In this study, a series of erlotinib-based 1,2,3-triazole compounds were designed and found to have inhibitory effects on IDO1 activity. Compound 14b showed the strongest inhibitory effect.
Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug resistance during chemotherapy. Indoleamine 2,3-dioxygenase-1 (IDO1) is a rate-limiting tryptophan catabolic enzyme that is activated in many human cancers. In this study, we designed a series of erlotinib-based 1,2,3-triazole compounds by combining erlotinib with phenyl or benzyl azide. Attentive FP prediction model was used to predict the bioactivity of those compounds. We discovered that most of the erlotinib-based 1,2,3-triazole compounds are capable of suppressing IDO1 activities in vitro experiments. Among them, compound 14b (IC50 = 0.59 +/- 0.05 mu M) had the strongest inhibitory effect on IDO1. In addition, compound 14b significantly inhibited tumor growth comparable to the antitumor activity of erlotinib and the IDO1 inhibitor epacadostat in murine tumor models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available